Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Clinical MedicineOpen Access

Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland

View Full Paper
Ask AI
Bookmark
Share

Authors

WKWiktor KruczekAFAleksandra FrątczakILIga Litwińska-Inglot

Discussion

Loading...

Member takes

Overview

Retrospective analysis compares real-world efficacy and safety of IL-17 inhibitors in psoriasis patients, indicating significant improvements.

Key Points

  • Bimekizumab showed the greatest effect for PASI reduction, outperforming secukinumab and ixekizumab significantly.
  • Efficacy was assessed through PASI, BSA, and DLQI scores, with significant improvements noted at week 12 for all agents.
  • The analysis utilized mixed-effects ANOVA to evaluate baseline factors influencing treatment outcomes in patients.
  • All treatments were well tolerated, with mild adverse events primarily involving upper respiratory infections.

Cite This Study

Kruczek et al. (2025) studied this question.

synapsesocial.com/papers/68c1b34654b1d3bfb60e9812https://doi.org/10.3390/jcm14155421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Il-17 Inhibitors in Moderate-To-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis2026
  2. 2Real‐world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single‐center retrospective study2024 · 35 citations
  3. 3Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study2026
  4. 4Real-world single-centre experience of bimekizumab in patients with psoriasis: a 16-week retrospective observational study2026
  5. 5Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials2025